Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and moni...

Descripción completa

Detalles Bibliográficos
Autores principales: Inzoli, Elena, Aroldi, Andrea, Piazza, Rocco, Gambacorti‐Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Critical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546318/
https://www.ncbi.nlm.nih.gov/pubmed/35384030
http://dx.doi.org/10.1002/ajh.26556
_version_ 1784805015125229568
author Inzoli, Elena
Aroldi, Andrea
Piazza, Rocco
Gambacorti‐Passerini, Carlo
author_facet Inzoli, Elena
Aroldi, Andrea
Piazza, Rocco
Gambacorti‐Passerini, Carlo
author_sort Inzoli, Elena
collection PubMed
description TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and monitoring. Clinical and biological factors associated with better outcomes do not yet offer a precise stratification of patients according to their risk of relapse. This article aims at reviewing the leading studies present in the field in order to define eligibility criteria for discontinuation and predictors of success.
format Online
Article
Text
id pubmed-9546318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-95463182022-10-14 Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success Inzoli, Elena Aroldi, Andrea Piazza, Rocco Gambacorti‐Passerini, Carlo Am J Hematol Critical Review TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and monitoring. Clinical and biological factors associated with better outcomes do not yet offer a precise stratification of patients according to their risk of relapse. This article aims at reviewing the leading studies present in the field in order to define eligibility criteria for discontinuation and predictors of success. John Wiley & Sons, Inc. 2022-04-12 2022-08 /pmc/articles/PMC9546318/ /pubmed/35384030 http://dx.doi.org/10.1002/ajh.26556 Text en © 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Critical Review
Inzoli, Elena
Aroldi, Andrea
Piazza, Rocco
Gambacorti‐Passerini, Carlo
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
title Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
title_full Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
title_fullStr Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
title_full_unstemmed Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
title_short Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
title_sort tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success
topic Critical Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546318/
https://www.ncbi.nlm.nih.gov/pubmed/35384030
http://dx.doi.org/10.1002/ajh.26556
work_keys_str_mv AT inzolielena tyrosinekinaseinhibitordiscontinuationinchronicmyeloidleukemiaeligibilitycriteriaandpredictorsofsuccess
AT aroldiandrea tyrosinekinaseinhibitordiscontinuationinchronicmyeloidleukemiaeligibilitycriteriaandpredictorsofsuccess
AT piazzarocco tyrosinekinaseinhibitordiscontinuationinchronicmyeloidleukemiaeligibilitycriteriaandpredictorsofsuccess
AT gambacortipasserinicarlo tyrosinekinaseinhibitordiscontinuationinchronicmyeloidleukemiaeligibilitycriteriaandpredictorsofsuccess

Ejemplares similares